IRL receives SEK 4.98 million from Vinnova for Phase I studies with IRL790

Vinnova (the Swedish Governmental Agency for Innovation Systems) supports IRL with SEK 4.98 million through the ”Innovationsprojekt i företag” call. The funding will co-finance IRLs Phase I studies with IRL790, a novel small-molecule treatment for dyskinesias and psychosis in Parkinson’s Disease (PD). The programme was recently approved for Phase I by the Swedish MPA (Läkemedelsverket).

“The continued and dedicated financial support from Vinnova for IRL and its development programme for IRL790 is very important for IRL. The support acknowledges the need for novel treatments for patients suffering from Parkinson’s disease and allows IRL to more rapidly move the IRL790 program forward.”

Joakim Tedroff, Chief Medical Officer, IRL